Ipilimumab

A quarter of patients with unresectable or metastatic angiosarcoma responded to a combination of ipilimumab and nivolumab, according to results of an analysis presented at the virtual Society for Immunotherapy of Cancer Annual Meeting.

Nivolumab plus ipilimumab induced durable responses among a subset of men with metastatic castration-resistant prostate cancer, according to results of the phase 2 CheckMate 650 study published in Cancer Cell.

The FDA approved nivolumab in combination with ipilimumab for the treatment of adults with unresectable malignant pleural mesothelioma, the first drug regimen approved for this population in 16 years.

A “sandwich” approach to melanoma treatment consisting of immunotherapy between two targeted therapy courses showed a trend toward improved total PFS, according to study results presented at ESMO Virtual Congress 2020.

National Prostate Cancer Awareness Month is observed every September.

Nivolumab plus ipilimumab- and pembrolizumab-based therapies may be the most cost-effective approaches in advanced melanoma, according to a study.

First-line nivolumab plus ipilimumab significantly extended OS compared with platinum-based chemotherapy for patients with unresectable malignant pleural mesothelioma, according to results of an interim analysis of the CheckMate 743 trial.

The FDA approved four regimens for non-small cell lung cancer since mid-May.

Adjuvant immunotherapy conferred a significant OS benefit among patients with resected stage IIIC melanoma, according to study results presented at American Association for Cancer Research Virtual Annual Meeting II.

Use of vitamin D supplements appeared to reduce risk for colitis among patients with cancer treated with immune checkpoint inhibitors, according to results of a retrospective study published in Cancer.